Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma: BCMA-Directed Therapies

Estimated Time
2.00 hours

Release Date
Apr 13, 2023

Expiration Date
Feb 08, 2024

Activity Description
Despite treatment advances, multiple myeloma remains incurable, with many patients relapsing or becoming resistant to treatment. Therefore, there is an urgent need for the continual development of novel and effective therapies. B-cell maturation antigen (BCMA)-directed therapies have presented a new avenue for patients with relapsed/refractory multiple myeloma (RRMM), as the different modalities have shown to be highly effective and tolerable. With an expansion to the treatment arsenal, it is important for oncology teams to stay abreast of the latest practice-changing data and guideline recommendations to improve patient outcomes.

Join us in this 3-part educational Med Table Talk® on Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM): BCMA-Directed Therapies as our experts from the US and Western Europe have a candid conversation about the role of BCMA in MM, the clinical implications of new and emerging BCMA-directed therapies, and practical strategies for treatment sequencing.


Accreditation and Disclosure Information

Target Audience
This activity is intended for practicing hematologic oncologists in the U.S. and Europe, physician associates, nurses, and pharmacists who provide care for individuals with Relapsed or Refractory Multiple Myeloma (RRMM).

Educational Objectives
After completing this activity, the participant should be better able to:  

  • Analyze the rationale for targeting BCMA in RRMM
  • Assess the potential roles of BCMA-targeted therapies in RRMM
  • Evaluate the clinical implications of emerging safety and efficacy data for BCMA-directed therapies
  • Incorporate strategies to prevent and manage adverse events of BCMA-targeted agents
  • Differentiate the mechanisms of drug resistance/loss of response for emerging BCMA-targeted approaches
  • Create strategies to improve diversity in clinical trial enrollment and access to care
  • Formulate strategies to use biomarkers appropriately to predict response to BCMA-targeted agents
  • Adopt best practices for sequencing and assessing response to BCMA-directed therapies  
  • Address the unique needs of special populations to overcome inequities

Program Agenda
Part 1 | Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy

  • Welcome
  • Role of BCMA in multiple myeloma
  • Overview of classes of BCMA-directed therapies in RRMM by mechanism of action
  • Latest updates on practice-changing data
  • Strategies for prevention and management of adverse events (AEs)
  • Diverse representation in clinical trials
  • Review of key points
  • Wrap-up

Part 2 | Navigating the Evidence: Pathways for New and Emerging BCMA Therapies

  • Welcome
  • Drug resistance mechanisms using standard first-line regimens
  • Efficacy and safety of emerging BCMA-directed therapies
  • Strategies to promote timely initiation of care for underrepresented communicates, increase clinical trial enrollment, and advocate for access to care
  • Review of key points
  • Wrap-up

Part 3 | Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy

  •  Welcome
  • Biomarker identification for prognosis and treatment selection
  • Optimal treatment decision making
  • Approaches to address health disparities in RRMM
  • Strategies to engage patients in shared decision making, improve patient outcomes, and advocate for access to care
  • Recap of key points
  • Wrap-up

Accreditation, Support and Credit

Joint Accreditation with Commendation logo

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ECMEC® Credit
ECMEC LogoThe European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu)

EBAH Credit EBAH Logo 1

EBAH Logo 2

Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma: BCMA-Directed Therapies has been reviewed and approved for CME-CPD accreditation by the European Board for Accreditation in Hematology (EBAH). The EBAH has approved this educational activity for a maximum number of 2.0 CME-CPD credits. Each participant should only collect credits for time that she/he actually spent in the educational activity

To collect your EBAH CME credits, register using the direct link and obtain an EBAH personal account number:

Support Statement
This activity is supported by educational grants from Pfizer, Bristol Myers Squibb, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Paula Rodríguez Otero, MD, PhD

Consultant in Hematology
Clínica Universidad de Navarra
Pamplona, Spain

Paula Rodríguez Otero, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Pfizer, Sanofi
Speakers’ Bureau: Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Regeneron, Sanofi

Adrienne A. Phillips, MD, MPH

Associate Professor of Clinical Medicine
Associate Fellowship Program Director
Department of Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, NY

Adrienne A. Phillips, MD, MPH, has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.

Melody Smith, MD, MS

Assistant Professor of Medicine
Stanford University, Department of Medicine
Division of Blood & Marrow Transplantation and Cellular Therapy
Stanford, CA

Melody Smith, MD, MS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Bristol Myers Squibb


Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, OH

Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Janssen, Pfizer, Sanofi

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, NY

Saad Z. Usmani, MD, MBA, FACP, has a financial interest/relationship or affiliation in the form of:
Research Grant: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Advisory Board/Consultant: Abbvie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio

Bruno Paiva, PharmD, PhD

Department of Hematology
Clinica Universidad de Navarra
Pamplona, Spain

Bruno Paiva, PharmD, PhD, has a financial interest/relationship or affiliation in the form of:
Research Grant: Amgen, Bristol Myers Squibb/Celgene, EngMab, GlaxoSmithKline, Roche, Sanofi, Takeda
Advisory Board/Consultant: Adaptive, Amgen, Bristol Myers Squibb/Celgene, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Roche, Sanofi, Takeda

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.

For Physicians requesting EBAH credit, please provide your EBAH personal account number.

About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.